Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Asset Writedowns and Impairment (2016 - 2026)

Champions Oncology has reported Asset Writedowns and Impairment over the past 8 years, most recently at -$30000.0 for Q1 2026.

  • For Q1 2026, Asset Writedowns and Impairment rose 25.0% year-over-year to -$30000.0; the TTM value through Jan 2026 reached $2000.0, up 101.27%, while the annual FY2025 figure was -$272000.0, 157.14% down from the prior year.
  • Asset Writedowns and Impairment for Q1 2026 was -$30000.0 at Champions Oncology, down from $13000.0 in the prior quarter.
  • Over five years, Asset Writedowns and Impairment peaked at $724000.0 in Q2 2023 and troughed at -$209000.0 in Q4 2024.
  • A 5-year average of $68928.6 and a median of $30500.0 in 2025 define the central range for Asset Writedowns and Impairment.
  • On a YoY basis, Asset Writedowns and Impairment climbed as much as 270.21% in 2024 and fell as far as 390.28% in 2024.
  • Year by year, Asset Writedowns and Impairment stood at $130000.0 in 2022, then plummeted by 44.62% to $72000.0 in 2023, then plummeted by 390.28% to -$209000.0 in 2024, then skyrocketed by 106.22% to $13000.0 in 2025, then tumbled by 330.77% to -$30000.0 in 2026.
  • Business Quant data shows Asset Writedowns and Impairment for CSBR at -$30000.0 in Q1 2026, $13000.0 in Q4 2025, and -$29000.0 in Q3 2025.